Pipeline Review
La Merie Business Intelligence, founded in 2002 by Ulrich Martin, MD, is a consultancy firm that draws on his deep expertise in the biopharmaceutical field. With a background as a physician focused on pharmacology and as a co-founder and CEO of a biotech firm dedicated to product development, Martin brings a wealth of knowledge to the company.
Outlet metrics
Global
#3356871
India
#304366
Health/Biotechnology and Pharmaceuticals
#322
Articles
-
1 week ago |
pipelinereview.com | Ulrich Martin
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has...
-
1 week ago |
pipelinereview.com | Ulrich Martin
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, PA, USA I May 9, 2025 I Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the...
-
1 week ago |
pipelinereview.com | Ulrich Martin
SHANGHAI, China I May 9, 2025 I Minghui Pharmaceutical (“Minghui”), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical (“Qilu”) for the development, manufacturing, and commercialization of its B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan).
-
1 week ago |
pipelinereview.com | Ulrich Martin
Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs.
-
1 week ago |
pipelinereview.com | Ulrich Martin
Temtokibart achieved positive results for the primary endpoint for the 3 highest doses in a phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis (AD) Temtokibart – also called LEO 138559 – is an investigational IL-22RA1 antagonist BALLERUP, Denmark I May 09, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline results of the phase 2b trial with temtokibart, an investigational IL-22RA1 antagonist, for the potential treatment of...
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Website
http://pipelinereview.comNo sites or socials found.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →